Melanoma

IMA203 showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high heterogeneity and gaps in melanoma-specific validation data.

Pembrolizumab showed strong anti-tumor activity in patients with unresectable desmoplastic melanoma.

Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, highlighting its potential as a treatment option.

During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in patients with advanced melanoma.

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete response letter.

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Theresa Medina, MD, discusses the clinical potential of lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant therapy and brain metastases management.

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant melanoma.

AI streamlines patient identification for clinical trials, significantly reducing review time while maintaining high accuracy, transforming oncology workflows.

Theresa Medina, MD, discusses the C-144-01 study of lifileucel in patients with advanced melanoma.

During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with metastatic melanoma.

Zeynep Eroglu, MD, discusses the use of a triplet regimen vs standard doublet therapy for the treatment of brain metastases in patients with melanoma.

Nivolumab and relatlimab show promising intracranial activity in melanoma brain metastases, highlighting potential for further research in resistant cases.

New findings reveal RP1 combined with nivolumab enhances response rates in advanced melanoma, especially with deep tumor injections, showing promising safety and efficacy.

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a manageable safety profile.

Adding cobolimab to dostarlimab as neoadjuvant treatment for high-risk resectable melanoma improved major pathological response rates and was tolerable.

Lifileucel therapy shows promising long-term survival and response rates in advanced melanoma patients, offering hope for those with limited treatment options.

Meghan Mooradian, MD, discusses findings and implications of the phase 2 NEO-MEL-T study.

An updated 4-year analysis indicates nivolumab/relatlimab offers comparable PFS and OS to nivolumab/ipilimumab in advanced melanoma, with lower toxicity.

During a live event, Ahmad Tarhini, MD, PhD, moderated a discussion on selection of immunotherapy regimens for patients with metastatic melanoma.